More than just a potential BREAKTHROUGH treatment for many cancers
•
1 like•45,812 views
An overview of Critical Outcome Technologies' lead cancer drug candidate, COTI-2, which represents a potential breakthrough treatment for many types of cancer. Critical Outcome Technologies is listed on the TSX Venture Exchange under the symbol COT.
Recommended
More Related Content
What's hot
What's hot (20)
Similar to More than just a potential BREAKTHROUGH treatment for many cancers
Similar to More than just a potential BREAKTHROUGH treatment for many cancers (20)
Recently uploaded
Recently uploaded (20)
More than just a potential BREAKTHROUGH treatment for many cancers
- 1. More than just a potential breakthrough treatment for many cancers June 2015
- 2. 22 Critical Outcome Technologies Inc. Rapidly developing targeted therapies to better meet the needs of patients TSX-V: COT OTCQB: COTQF
- 3. 3 Highlights 1 2 3 COTI-2 – lead program in oncology entering Phase 1 clinical trial in 2015 CHEMSAS – proprietary drug discovery engine using machine-based learning Strong pipeline of opportunities in oncology and other therapeutic areas
- 4. 4 COTI-2: a promising advance Potential breakthrough treatment for many cancers Effective against many common cancers with a p53 gene mutation > 50% of all human cancers have a p53 mutation (eg. ~ 95% of serous ovarian cancers)
- 5. 5 COTI-2 background N N N H S N N N 3rd generation Thiosemicarbazone A small molecule discovered by our CHEMSAS process Engineered for low toxicity and easily synthesized in 3 steps Demonstrates strong in vitro and in vivo activity 5
- 6. 6 COTI-2: first- and best-in-class potential Novel p53-dependent mechanism of action Orally bio-available and effective at low dose Low toxicity in preclinical development Opportunity for single agent and combination therapy Strong IP protection in place
- 7. 7 COTI-2 and tumor volumes Tumors significantly reduced by COTI-2 in all treatment groups relative to vehicle control
- 8. 8 COTI-2 reduces p53 resistant protein levels COTI-2 significantly reduces p53 mutant protein levels and significantly increases wild-type p53 protein levels in TOV- 112D cells likely by inducing a conformational change •(*) Significant difference in p53 protein levels between COTI-2 treated and untreated cells (control) Mutant p53 Levels in the presence/absence of COTI-2 0 20 40 60 80 100 TOV-112D H460 MeanFluorescenceIntensity(ArbitraryUnits) Cell Line Control COTI-2 *
- 9. 9 COTI-2: effects on p53 protein levels COTI-2 has no significant effect on p53 protein levels in the H460 cell line, which do not carry the mutant p53 protein •(*) Significant difference in p53 protein levels between COTI-2 treated and untreated cells (control) Wild-type p53 Levels in the Presence/Absence of COTI-2 0 20 40 60 80 100 120 TOV-112D H460 MeanFluorescenceIntensity(ArbitraryUnits) Cell Line Control COTI-2 *
- 10. 10 MD Anderson relationship 10 Confirmed COTI-2’s novel p53 dependent MOA Confirmed selective & potent anti-cancer activity Identified effective dosage 60% lower than in prior animal experiments
- 11. 11 COTI-2: the pathway to the clinic Granted orphan drug status for ovarian cancer by FDA in June 2014 Completed final pre-clinical studies Signed LOI with MD Anderson for Phase 1 clinical development Grant of Investigational New Drug status in May 2015 Commence Phase 1 clinical trial in 3rd quarter of calendar 2015
- 12. 12 COTI-2: next steps 12 Complete Phase 1: 46 patients in gynecologic cancers Expand indications and combination therapies Phase 2: add value – create partnerships
- 13. 1313 Proprietary, machine learning (AI) based drug discovery platform technology Big Data analysis solutions Building a robust pipeline with CHEMSAS®
- 14. 14 Costly failed attempts occur quickly & cheaply in computer simulations, not the ‘wet lab’ Increased probability of clinical & commercial success Database driven computational replication of traditional ‘wet lab’ drug discovery process 14 Advantages of CHEMSAS®
- 15. 15 Drugs in our pipeline Therapy Library /Compound Target CHEMSAS Lead Selection Synthesis Preclinical Phase 1 Oncology COTI-2 AML Colon Small Cell Lung Cancer Library COTI-219 COTI-4 COTI-58 6 other leads Plus projects for MRSA, Multiple sclerosis, Alzheimer’s, and HIV Integrase Inhibitors
- 16. 16 Summary 1 2 3 COTI-2 – lead program in oncology entering Phase 1 clinical trial in 2015 CHEMSAS – proprietary drug discovery engine using machine-based learning Strong pipeline of opportunities in oncology and other therapeutic areas
- 17. 17 When used anywhere in this presentation, whether oral or written, the words expects, believes, anticipates, estimates and similar expressions are intended to identify forward-looking statements. Forward-looking statements may include statements addressing future financial and operating results of Critical Outcome Technologies Inc. (COTI). COTI bases these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI’s strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of potential patent issues, competition, changes in economic conditions, and other risks described in COTI’s public documents such as press releases and filings with the Toronto Stock Exchange and the Ontario Securities Commission. All forward-looking statements are qualified in their entirety by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this presentation. These forward-looking statements speak only as of the date of this presentation. Disclaimer
- 18. Follow CriticalOutcome on Twitter, Facebook, YouTube and SlideShare